高流量氧疗在长期氧疗中的效果(HILOT):一项多中心、基于注册的随机临床试验研究方案
该研究为一项多中心、基于注册的随机对照试验,纳入瑞典10个中心接受长期氧疗的慢性呼吸衰竭患者(COPD n=270,ILD n=40),按1:1随机分为标准长期氧疗组与长期氧疗联合夜间及日间按需高流量氧疗组。主要结局为COPD患者1年内首次住院或死亡时间。研究旨在结合前瞻性随机试验与国家大型注册数据,改善长期氧疗的循证使用。
要点
- HILOT研究为基于瑞典呼吸衰竭注册(Swedevox)的多中心随机对照试验。
- COPD患者270例、ILD患者40例,1:1随机接受长期氧疗或联合高流量氧疗。
- 主要结局为COPD患者1年内首次住院或死亡时间,数据来自国家注册和患者问卷。
核心结论
- 该基于注册的随机对照试验旨在结合前瞻性随机试验与国家大型临床注册的优势,以改善长期氧疗的循证使用。
研究设计与样本
- 研究为基于注册的随机对照试验(R-RCT),在瑞典10个二级医疗中心及瑞典呼吸衰竭注册(Swedevox)内开展。
- 纳入因COPD(n=270)或ILD(n=40)导致慢性呼吸衰竭并正在接受长期氧疗的患者,按1:1随机分为标准长期氧疗对照组或长期氧疗联合夜间及日间按需高流量氧疗干预组。
- 高流量氧疗使用ResMed Lumis HFT系统和AcuCare HFNC Cannula提供。
主要发现
- 主要结局为COPD患者1年内首次住院或死亡的时间。
- 次要结局包括症状、健康相关结局(HRQL)、健康经济学、不良事件,并探索高流量氧疗对ILD所致慢性呼吸衰竭患者的效果。
- 结局数据将从国家注册和患者3个月及12个月时的问卷中获取。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The use of high-flow oxygen therapy (HFOT) compared with standard low-flow oxygen therapy (LFOT) may improve outcomes in people with oxygen-dependent chronic respiratory failure (CRF). The primary aim of this multicentre trial was to evaluate HFOT in addition to LFOT, compared with regular LFOT in people with CRF due to chronic obstructive pulmonary disease (COPD) or interstitial lung disease (ILD). METHODS: Registry-based randomised controlled trial (R-RCT) of people on LFOT for CRF due to COPD (n = 270) and ILD (n = 40), at ten Swedish secondary care centres within the Swedish Register for Respiratory Failure (Swedevox). People with ongoing LFOT are randomised in a 1:1 ratio to standard treatment with LFOT (control) or LFOT with added HFOT during nighttime and at the patient's discretion daytime (intervention). HFOT is provided using the ResMed Lumis HFT system and the AcuCare HFNC Cannula. Primary outcome is time to first hospitalisation or death up to 1 year in people with COPD. Secondary outcomes include symptoms, health-related outcomes (HRQL), health-economics, adverse events, and to explore the effects of HFOT in people with CRF due to ILD. Outcome data will be obtained from national registries and from patient questionnaires at 3 and 12 months. DISCUSSION: This R-RCT will combine the advantages of a prospective randomised trial and large clinical national registries to improve the evidence-based use of long-term oxygen therapy. Recruitment started in June 2024 and is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT06247397. Registered 2024-02-07.
引用
- Sundh J, Ljunggren M, Palm A, et al. Effect of HIgh-Flow Therapy in Long-Term Oxygen Therapy (HILOT): study protocol for a multicentre, registry-based, randomised clinical trial. Trials. 2026. PMID: 41634827. doi:10.1186/s13063-026-09488-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。